Merck & Co. Inc

Commercial

Salini Mohanty - Chief Investigator - Merck & Co. Inc - PennsylvaniaUSABélène Podmore - Corresponding Applicant - OXON Epidemiology - SpainEric Sarpong - Collaborator - Merck & Co.Inc.Ian Matthews - Collaborator - Merck & Co. Inc - PennsylvaniaUSAIgnacio Mendez - Collaborator - OXON Epidemiology - SpainJessica Weaver - Collaborator - Merck & Co.Inc.Julia Agúndez - Collaborator - OXON Epidemiology - SpainLaura Spowart - Collaborator - MSD VaccinsLorena Baquero Portela - Collaborator - OXON Epidemiology - SpainNawab Qizilbash - Collaborator - OXON Epidemiology - SpainRebeca Gonzalez Eriksen - Collaborator - OXON Epidemiology - SpainSergio Eslava - Collaborator - Merck & Co. Inc - PennsylvaniaUSASusan Farrow - Collaborator - Merck & Co. Inc - PennsylvaniaUSATianyan Hu - Collaborator - Merck & Co. Inc - PennsylvaniaUSA

CPRD881

Pneumococcal disease is a lung infection causes by a wide range of microorganisms such as the bacteria Streptococcus pneumoniae. This can cause mild to severe symptoms that affect each patient differently; however, it is a highly preventable disease thanks to vaccination.

The aim of this study is to examine invasive and non-invasive pneumococcal disease incidence in England in primary care and inpatient settings from 2003 to 2019, including before and after the introduction of PCV7 and PCV13 vaccines and the late post PCV13 period. The study will additionally estimate healthcare resource utilisation (HCRU) and costs associated with these episodes.

05/01/2021

Release